219 related articles for article (PubMed ID: 31173207)
1. Serum and tissue proteomic signatures of patients with hepatocellular carcinoma using 2‑D gel electrophoresis.
Peng H; Yan Z; Zeng X; Zhang S; Jiang H; Huang H; Zhuo H
Mol Med Rep; 2019 Aug; 20(2):1025-1038. PubMed ID: 31173207
[TBL] [Abstract][Full Text] [Related]
2. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies.
Ritorto MS; Borlak J
J Proteome Res; 2011 Jul; 10(7):3012-30. PubMed ID: 21644509
[TBL] [Abstract][Full Text] [Related]
3. Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma.
Junrong T; Huancheng Z; Feng H; Yi G; Xiaoqin Y; Zhengmao L; Hong Z; Jianying Z; Yin W; Yuanhang H; Jianlin Z; Longhua S; Guolin H
J Biosci; 2011 Sep; 36(4):659-68. PubMed ID: 21857112
[TBL] [Abstract][Full Text] [Related]
4. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
[TBL] [Abstract][Full Text] [Related]
5. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.
Yi X; Luk JM; Lee NP; Peng J; Leng X; Guan XY; Lau GK; Beretta L; Fan ST
Mol Cell Proteomics; 2008 Feb; 7(2):315-25. PubMed ID: 17934217
[TBL] [Abstract][Full Text] [Related]
6. Expression of Raf kinase inhibitor protein in human hepatoma tissues by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight methods.
Tsao DA; Shiau YF; Tseng CS; Chang HR
Indian J Cancer; 2016; 53(2):216-219. PubMed ID: 28071612
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.
Guo Y; Zhao J; Bi J; Wu Q; Wang X; Lai Q
J Hematol Oncol; 2012 Jul; 5():37. PubMed ID: 22760167
[TBL] [Abstract][Full Text] [Related]
8. A novel lncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1.
Yu S; Li N; Huang Z; Chen R; Yi P; Kang R; Tang D; Hu X; Fan X
Cell Death Dis; 2018 Dec; 9(12):1184. PubMed ID: 30518748
[TBL] [Abstract][Full Text] [Related]
9. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
[TBL] [Abstract][Full Text] [Related]
10. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues.
Sun W; Xing B; Sun Y; Du X; Lu M; Hao C; Lu Z; Mi W; Wu S; Wei H; Gao X; Zhu Y; Jiang Y; Qian X; He F
Mol Cell Proteomics; 2007 Oct; 6(10):1798-808. PubMed ID: 17627933
[TBL] [Abstract][Full Text] [Related]
11. SELDI-TOF MS Analysis of Hepatocellular Carcinoma in an Australian Cohort.
Schlichtemeier SM; Nahm CB; Xue A; Gill AJ; Smith RC; Hugh TJ
J Surg Res; 2019 Jun; 238():127-136. PubMed ID: 30771682
[TBL] [Abstract][Full Text] [Related]
12. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach.
Qiao B; Wang J; Xie J; Niu Y; Ye S; Wan Q; Ye Q
Int J Mol Med; 2012 May; 29(5):832-40. PubMed ID: 22344546
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma.
Park KS; Kim H; Kim NG; Cho SY; Choi KH; Seong JK; Paik YK
Hepatology; 2002 Jun; 35(6):1459-66. PubMed ID: 12029631
[TBL] [Abstract][Full Text] [Related]
14. Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.
Zheng ZK; Pang C; Yang Y; Duan Q; Zhang J; Liu WC
J Int Med Res; 2018 Jan; 46(1):348-356. PubMed ID: 28856933
[TBL] [Abstract][Full Text] [Related]
15. Identification of two portal vein tumor thrombosis associated proteins in hepatocellular carcinoma: protein disulfide-isomerase A6 and apolipoprotein A-I.
Xu X; Wei X; Ling Q; Cheng J; Zhou B; Xie H; Zhou L; Zheng S
J Gastroenterol Hepatol; 2011 Dec; 26(12):1787-94. PubMed ID: 21649721
[TBL] [Abstract][Full Text] [Related]
16. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.
Orimo T; Ojima H; Hiraoka N; Saito S; Kosuge T; Kakisaka T; Yokoo H; Nakanishi K; Kamiyama T; Todo S; Hirohashi S; Kondo T
Hepatology; 2008 Dec; 48(6):1851-63. PubMed ID: 18937283
[TBL] [Abstract][Full Text] [Related]
17. RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma.
Shang R; Wang J; Sun W; Dai B; Ruan B; Zhang Z; Yang X; Gao Y; Qu S; Lv X; Tao K; Wang L; Dou K; Wang D
Tumour Biol; 2016 Apr; 37(4):5097-105. PubMed ID: 26546438
[TBL] [Abstract][Full Text] [Related]
18. Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients.
Tan GS; Lim KH; Tan HT; Khoo ML; Tan SH; Toh HC; Ching Ming Chung M
J Proteome Res; 2014 Nov; 13(11):4833-46. PubMed ID: 24946162
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potential key genes in very early hepatocellular carcinoma.
Wu M; Liu Z; Li X; Zhang A; Lin D; Li N
World J Surg Oncol; 2019 May; 17(1):77. PubMed ID: 31043166
[TBL] [Abstract][Full Text] [Related]
20. Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma.
Wong KF; Luk JM
Methods Mol Biol; 2012; 909():295-310. PubMed ID: 22903723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
